Peanut
- Generic Name
- Peanut
- Brand Names
- Palforzia 12 Mg (level 3), Palforzia 120 Mg (level 7), Palforzia 160 Mg (level 8), Palforzia 20 Mg (level 4), Palforzia 200 Mg (level 9), Palforzia 240 Mg (level 10), Palforzia 3 Mg (level 1), Palforzia 300 Mg (level 11), Palforzia 40 Mg (level 5), Palforzia 6 Mg (level 2), Palforzia 80 Mg (level 6), Palforzia Initial Dose Escalation
- Drug Type
- Biotech
- Unique Ingredient Identifier
- QE1QX6B99R
- Background
Peanut allergenic extract is used in allergenic testing.
Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy
- Conditions
- Peanut Allergy
- Interventions
- Dietary Supplement: Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Murdoch Childrens Research Institute
- Registration Number
- NCT06297083
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 600
- Registration Number
- NCT05741476
- Locations
- 🇬🇧
DBV Investigative Site, Southampton, United Kingdom
🇺🇸DBV Investigative site, Atlanta, Georgia, United States
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Allergy Therapeutics
- Target Recruit Count
- 46
- Registration Number
- NCT05476497
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- ALK-Abelló A/S
- Target Recruit Count
- 192
- Registration Number
- NCT05440643
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Los Angeles - USC School of Medicine, Los Angeles, California, United States
🇺🇸UCLA - Pediatrics, Los Angeles, California, United States
Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 12
- Registration Number
- NCT04974970
- Locations
- 🇨🇭
Pediatric allergy unit, Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland
Viaskin® Peanut (DBV712) Expanded Access Protocol
- Conditions
- Peanut Allergy
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- DBV Technologies
- Registration Number
- NCT04371627
Food Oral Immunotherapy for Peanut Allergy
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT04222491
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Boiled Peanut Oral Immunotherapy
- Conditions
- Peanut Hypersensitivity
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Alton Melton
- Target Recruit Count
- 10
- Registration Number
- NCT04090203
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
- Conditions
- Food AllergyPeanut Allergy
- Interventions
- Other: Continued peanut avoidance
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Scott Sicherer
- Target Recruit Count
- 73
- Registration Number
- NCT03907397
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Peanuts and Glycemic Control
- Conditions
- Type2 DiabetesCardiovascular Diseases
- Interventions
- Drug: High carbohydrate snack
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Penn State University
- Target Recruit Count
- 51
- Registration Number
- NCT03654651
- Locations
- 🇺🇸
Pennsylvania State University, University Park, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.